Delapril plus indapamide: a review of the combination in the treatment of hypertension.

Abstract

Although many data indicate that the management of hypertension has improved over the last two decades, there is still a large proportion of hypertensive individuals who do not receive adequate management of their blood pressure (BP). Combination therapy with two or more antihypertensive agents from different drug classes is increasingly being recognised as the most effective means of achieving target BP values by pharmacological means, particularly in the large number of patients in whom monotherapy proves to be ineffective. Use of an angiotensin-converting enzyme (ACE) inhibitor combined with a diuretic is a well established antihypertensive combination that is very effective because of the different, yet synergistic, mechanisms of actions of agents from these two drug classes. Delapril is a potent antihypertensive ACE inhibitor, and indapamide is a thiazide-like diuretic with additional antihypertensive properties. The combination of delapril and indapamide provides renoprotective effects, and indapamide is also cardioprotective. Use of these two drugs together is therefore a rational selection for combination therapy, and one that has consistently demonstrated lowering of BP to target values with a level of efficacy that is at least as good as other combinations of ACE inhibitors and diuretics. This combination has also been found to provide favourable effects on haemodynamic parameters, including left ventricular mass index and ejection fraction. Furthermore, combining an ACE inhibitor and a thiazide-type diuretic has been associated with a decreased risk of stroke and is recommended for patients with cerebrovascular disease, a setting in which the combination of delapril and indapamide has therapeutic potential. Because of the additive mechanisms of delapril and indapamide, the dose required for an effective antihypertensive effect is relatively low, and the combination is well tolerated at such doses. In particular, metabolic effects normally associated with diuretics are rare at the therapeutic dose of indapamide used in combination with delapril, making the combination suitable for patients with metabolic disorders in whom diuretic therapy would otherwise not be recommended. Delapril 30 mg and indapamide 2.5mg have been combined in a fixed combination, offering the convenience of a one-tablet-per-day antihypertensive drug regimen for most patients, which, along with good tolerability, helps to address the issue of noncompliance.

• Authors: Luca Cavalieri, Giovanni Cremonesi
• Journal: Clinical drug investigation (Clin Drug Investig) Vol. 27 Issue 6 Pg. 367-80 ( 2007) ISSN: 1173-2563 [Print] New Zealand
• PMID: 17506588 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antihypertensive Agents
• Drug Combinations
• Indans
• Indapamide
• delapril

Topics

• Animals
• Antihypertensive Agents (adverse effects, pharmacology, therapeutic use)
• Drug Combinations
• Humans
• Hypertension (drug therapy)
• Indans (adverse effects, pharmacology, therapeutic use)
• Indapamide (adverse effects, pharmacology, therapeutic use)